@misc{10481/101458,
year = {2014},
month = {10},
url = {https://hdl.handle.net/10481/101458},
abstract = {Objective: Pancreatic ductal adenocarcinoma is a deadly disease because of late diagnosis and chemoresistance. We aimed to find a panel of serum cytokines representing diagnostic and predictive biomarkers for pancreatic cancer. Methods: A cytokine antibody array was performed to simultaneously identify 507 cytokines in sera of patients with pancreatic cancer and healthy controls. The nonparametric Mann-Whitney U test was used to pairwise compare the controls, the pretreated patients, and the posttreated patients. Fold changes greater than or equal to 1.5 or less than or equal to 1/1.5 were considered significant. Receiver operating characteristic curves were used to assess the performance of the model. A leave-one-out cross-validation was used for estimating prediction error. Results: Comparing the sera of pretreated patients against the control samples, the cytokines fibroblast growth factor 10 (FGF-10/keratinocyte growth factor-2 (KGF-2), chemokine (C-X-C motif) ligand 11 interferon inducible T cell alpha chemokine (I-TAC)/chemokine [C-X-C motif] ligand 11 (CXCL11), oncostatin M (OSM), osteoactivin/glycoprotein nonmetastatic melanoma protein B, and stem cell factor (SCF) were found significantly overexpressed. Besides, the cytokines CD30 ligand/tumor necrosis factor superfamily, member 8 (TNFSF8), chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF were differentially expressed in response to treatment. Conclusions : We propose a role for FGF-10/KGF-2, I-TAC/CXCL11, OSM, osteoactivin/glycoprotein nonmetastatic melanoma protein B, and SCF as novel diagnostic biomarkers. CD30 ligand/TNFSF8, chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF might represent as predictive biomarkers for gemcitabine and erlotinib response of patients with pancreatic cancer.},
organization = {This study was supported by Roche Farma S.A. (REF H/OH-TAR-10/131 and REF H/OH-TRR-08/59) and Instituto de Salud Carlos III
(clinical trial REF EC08/00009).},
publisher = {Lippincott Williams & Wilkins},
keywords = {serum diagnosis biomarker},
keywords = {serum predictive biomarker},
keywords = {pancreatic cancer},
keywords = {cytokines},
title = {Serum Cytokine Profile in Patients With Pancreatic Cancer},
doi = {10.1097/MPA.0000000000000155},
author = {Torres Perales, Carolina and Perales Romero, Sonia and Alejandre Pérez, María José and Iglesias, José and Palomino Morales, Rogelio Jesús and Martín Hernández, Miguel and Caba Pérez, Octavio and Prados Salazar, José Carlos and Aránega Jiménez, Antonia and Delgado, Juan Ramón and Irigoyen, Antonio and Ortuño Guzmán, Francisco Manuel and Rojas Ruiz, Ignacio and Linares Gil, Ana María},
}